Collplant Biotechnologies Ltd Market Cap ($7.88 Million)
Market Cap & Net Worth: Collplant Biotechnologies Ltd (CLGN)
Collplant Biotechnologies Ltd market cap. Collplant Biotechnologies Ltd (NASDAQ:CLGN) has a market capitalization of $7.88 Million ($7.88 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #27511 globally and #5701 in its home market, demonstrating a 9.60% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Collplant Biotechnologies Ltd's stock price $4.11 by its total outstanding shares 12803006 (12.80 Million). Also see CLGN operating cash flow for how efficiently the company converts equity into cash flow.
Collplant Biotechnologies Ltd Market Cap History (2015–2026)
Collplant Biotechnologies Ltd market cap history from 2015 to 2026. Data shows change from $307.46 Million to $52.62 Million (-14.50% CAGR). Check Collplant Biotechnologies Ltd stock quote for real-time trading data and today's change.
Index Memberships
Collplant Biotechnologies Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #778 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2518 of 3165 |
Weight: Collplant Biotechnologies Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Collplant Biotechnologies Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Collplant Biotechnologies Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore CLGN net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
89.50x
Collplant Biotechnologies Ltd's market cap is 89.50 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $68.71 Million | $75.91K | -$7.27 Million | 905.19x | N/A |
| 2017 | $97.17 Million | $479.92K | -$5.80 Million | 202.48x | N/A |
| 2018 | $53.77 Million | $4.79 Million | -$6.25 Million | 11.23x | N/A |
| 2019 | $72.98 Million | $2.32 Million | -$11.16 Million | 31.48x | N/A |
| 2020 | $137.89 Million | $6.14 Million | -$5.77 Million | 22.47x | N/A |
| 2021 | $209.46 Million | $15.64 Million | $237.00K | 13.39x | 883.79x |
| 2022 | $106.91 Million | $299.00K | -$16.93 Million | 357.54x | N/A |
| 2023 | $81.81 Million | $10.96 Million | -$7.02 Million | 7.47x | N/A |
| 2024 | $46.09 Million | $515.00K | -$16.61 Million | 89.50x | N/A |
Competitor Companies of CLGN by Market Capitalization
Companies near Collplant Biotechnologies Ltd in the global market cap rankings as of November 4, 2026. Also see balance sheet size of Collplant Biotechnologies Ltd for a full breakdown of the balance sheet.
Key companies related to Collplant Biotechnologies Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Collplant Biotechnologies Ltd (2015–2026)
Market capitalization of Collplant Biotechnologies Ltd from 2015 to today. Between 2015 and today, Collplant Biotechnologies Ltd's market cap moved from $307.46 Million to $ 52.62 Million, with a yearly change of -14.50%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $52.62 Million | +193.57% |
| 2025 | $17.92 Million | -61.11% |
| 2024 | $46.09 Million | -43.66% |
| 2023 | $81.81 Million | -23.47% |
| 2022 | $106.91 Million | -48.96% |
| 2021 | $209.46 Million | +51.90% |
| 2020 | $137.89 Million | +88.95% |
| 2019 | $72.98 Million | +35.71% |
| 2018 | $53.77 Million | -44.66% |
| 2017 | $97.17 Million | +41.42% |
| 2016 | $68.71 Million | -77.65% |
| 2015 | $307.46 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Collplant Biotechnologies Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $7.88 Million USD |
| MoneyControl | $7.88 Million USD |
| MarketWatch | $7.88 Million USD |
| marketcap.company | $7.88 Million USD |
| Reuters | $7.88 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Collplant Biotechnologies Ltd
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. The company's products are based on its recombinant human collagen (rhCollagen) that is produced using its proprietary technology. It offers regenerative dermal … Read more